Background {#Sec1}
==========

Cytomegalovirus, a natural pathogen of humans belongs to a genus of viruses in the Herpesvirales order, Herpesviridae family and Betaherpesvirinae subfamily. It has been shown that CMV is able to become latent in the body for a long period of time. CMV infections have been found to be associated with salivary glands in humans \[[@CR1]\]. It is the most common cause of congenital infections worldwide (0.2 to 2.2%) which may be symptomatic or asymptomatic at birth \[[@CR2], [@CR3]\]. The prevalence of congenital CMV (cCMV) infection varies substantially in developing countries, both within and between countries, with some reported values as high as 6--14% \[[@CR4], [@CR5]\]. There is a paucity of data concerning the prevalence of CMV infection in Iran and the few available reports deal mainly with the infections in pregnant women**.** However, there are no reports on the prevalence of cCMV in symptomatic infants from Iran. Most infants (85%--90%) with cCMV infection lack clinical abnormalities (asymptomatic cCMV) and are not identified in the newborn nurseries \[[@CR6]\]. Approximately 10--15% of these and about 50% of infants with clinical abnormalities at birth (symptomatic cCMV) will develop sequelae, including sensorineural hearing loss (SNHL), mental retardation, microcephaly, developmental delay, seizure disorders, and cerebral palsy. Damage in the fetal brain seems to be associated with an immune inflammatory response to CMV in the infected brain as well as that of a direct cytopathic effect of the virus on precursor cells of the neuroepithelium \[[@CR7], [@CR8]\]. Infants congenitally infected with CMV may benefit from antiviral therapy, especially if the treatment is initiated within the first month of life. The decision to treat an infected infant with antiviral therapy is based on the presence or absence of symptoms and on the immune status of the infant. Routine newborn physical examinations fail to identify the majority of the children (\>90%) with congenital CMV infection. In addition, CMV-related SNHL might develop after birth and may not be diagnosed by means of hearing screening of newborns \[[@CR9]\].

Diagnosis of the congenital infection should be made before the third week of life since after this period, it is not possible to assess whether viral transmission occurred through the placenta or through external sources such as the birth canal, saliva, or breast milk \[[@CR3], [@CR10]\].

A variety of methods have been developed for diagnosis of congenital CMV infection using saliva, urine, and dried-blood-spot specimens obtained from the newborns \[[@CR2], [@CR11], [@CR12]\]. Culture-based testing of urine and saliva specimens has been the standard method to identify infants with congenital CMV infection \[[@CR11], [@CR13]\]. However, in most medical laboratories of developing countries, including Iran, culture-based methods are expensive, difficult to perform and even with the rapid test it takes 24 to 36 h to get the results.

In many studies, it has been shown that agreement between immunoassay kits varies from 56% to 75% with a sensitivity of between 30% and 88% \[[@CR14]\]. Due to passive transfer of antibody across the placenta, detection of CMV IgG in the neonates is not very helpful in making a diagnosis of congenital infection \[[@CR15]\]. Vauloup-Fellous et al. reported high sensitivities and specificities of real time PCR (94.7--100% and 94.7--97.3% respectively) compared with the virologic methods \[[@CR16]\]. Albanna et al. showed that PCR using urine sample is a more sensitive and specific technique for detection of congenital CMV infection than CMV IgM testing. Therefore, PCR by being more cost effective, less cumbersome and less time consuming compared with viral culture, may be the method of choice for diagnosis of congenital CMV infection in suspected neonates \[[@CR17]\].

Rapid and correct diagnosis of congenital CMV infection in neonates is very important for the correct therapy selection and proper management of the cases.

ELISA based detection of CMV specific IgM antibodies has been is still in use for diagnosis of current or congenital CMV infection although, low specificity and sensitivity of the ELISA systems have been reported in some evaluation studies \[[@CR17], [@CR18]\].

Despite the importance of CMV infection, many children who are congenitally infected with virus remain undetected as diagnosis is not performed by the public health systems in many countries, Iran being among them. This study was aimed to evaluate the prevalence of CMV congenital infections in symptomatic infants under 3 weeks in Tehran, Iran. The current study was also designed to evaluate the usefulness of immunological assays (IgG and IgM) of serum obtained from symptomatic newborns for detection of CMV infection in a population study.

Methods {#Sec2}
=======

Sample population {#Sec3}
-----------------

Clinical signs and symptoms of congenital CMV infections were registered including microcephaly, small for gestational age, petechiae, purpura, seizures, jaundice, hepatosplenomegaly, chorioretinitis, and deafness. Neonates might have one or more than one of these signs or symptoms. Complete clinical examination of all the neonates was done by the pediatricians.

This cross sectional study was conducted from June 2013 to December 2014 with approval from "Ethics Committee" of Pasteur Institute of Iran. Parental written consent was obtained for all the infants enrolled in the study.

Blood and urine samples were collected from 100 symptomatic neonates (under 3 weeks), who were referred to Tehran medical centers, suspected of congenital infection. Urine from collection bags was transferred to the strile tubes and blood samples were kept at room temperature for coagulation prior to centrifugation at 2000×*g* for 20 min. Samples, both urine and sera were then frozen at −20°C until use. Urine samples were centrifuged at 1500 rpm for 20 min and the pellets washed three times with 1X phosphate buffered saline (PBS, pH = 7). DNA was extracted from urine by column purification using PCR template purification kits (Roche, Germany) according to the manufacturer's protocol.

Serology {#Sec4}
--------

The presences of CMV-specific IgM and IgG in serum samples were measured using commercial microplate enzyme immunoassay kits (Vircell microbiologists, Spain). The manufacturer's instructions were used for procedure and interpretation of the results.

PCR amplification {#Sec5}
-----------------

A fluorescent end point PCR (FEP-PCR) was carried out on the DNA extracted from all urine samples using the CMV genome specific primers and probes. The commercial CMV PCR kit was used to detect viral DNA (DNA technology, Russia). The kit has the CE/IVD certificate with 95% and 99.5% sensitivity and specificity, respectively. This sensitivity has been evaluated using serial dilutions of "1st WHO International Standard for Human Cytomegalovirus for Nucleic Acid Amplification Techniques" (NIBSC code: 09/162) (NIBSC, England). The minimum detection limit (MOD) of the kit is 5 copies/reaction. The amplification and cycling conditions were according to the manufacturer's protocol. An internal DNA, positive and negative controls were included in all PCR runs and amplifications were performed in duplicate (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Electrophoresis result of PCR amplified HCMV DNA of 5 urine samples (280 bp) in 1.5% agarose gel stained with ethidium bromide and photographed under UV light. M = 50 bp DNA ladder. C+ = positive control. C- = negative control. Lane 1--5 = patients sample

Statistical analysis {#Sec6}
--------------------

Chi-squared test (X2), using SPSS (version 16) was used to compare the PCR and serologic results. The *p* values of ≤0.05 were considered statistically significant. Similar analyses were done for the differences of sex, gestation time, and age of the infants studied.

STATA 14 was used to calculate the sensitivity, specificity, positive and negative predictive values (PPV, NPV) of the serologic tests against PCR as the reference method.

Results {#Sec7}
=======

The study population consisted of 47 (47%) males and 53 (53%) females. Twenty two out of 47 (46.8%) males and thirthy three of 53 (62.3%) females were positive for CMV-DNA (Table [1](#Tab1){ref-type="table"}). The age demographic data of the study population are presented in Table [1](#Tab1){ref-type="table"}.Table 1Demographic data of neonates with congenital infectionsCMV-DNAP valuePosNegTotalGenderM24(51.1%)23(48.9%)470.186F34(64.2%)19 (35.8%)531st week15 (34.1%)29 (65.9%)440.0^a^\
0.007^b^Age2nd week29 (80.1%)7 (19.4%)363rd week14 (70%)6 (30%)20Gestational age\<37 week15 (40.5%)22 (59.5%)370.007≥37 week43 (63.37%)20(31.7%)63^a^ *p* value of the analysis of the 1st week against 2nd week of the age^b^ *p* value of the analysis of the 1st week against 3rd week of the age

Of the 100 infants, 44, 36, and 20 were in the first, second, and the third weeks of the birth, respectively. Thirthy seven of the 100 symptomatic infants were premature (gestation \<37 weeks), in 10 (27%) of which CMV-DNA was detected in their urine samples and of the remaining 63 fullterm neonates 18 (28.6%) were PCR-positive. Our data did not show any association between CMV infection, gender or the age of the infants diagnosed by PCR (*p* = 0.186, 0.375, respectively). Furthermore, no statistically significant difference was found between gestation age of the patients (fullterm: ≥ 37 weeks and premature: \<37 weeks) and a PCR positive result of CMV-DNA (*p* = 0.224).

The respiratory problems and seizures were the most common symptoms, 31% and 24%, respectively, followed by microcephaly 22%,jaundice 20%, and hepatosplenomegaly 15%. Other clinical signs such as hydrocephaly, calcification, splenomegaly, anemia, and meningitis, were observed in 16% of the cases (Table [2](#Tab2){ref-type="table"}). Most of the infants had more than one clinical symptom.Table 2Comparison of clinical remarks and urine CMV DNA incretion in symptomatic congenital infantsCMV DNAClinical symptomsNo of patientsPos.Neg.*P* valueRespiratory problems3117(55%)14(45%)0.590Neurologic- one or more of the following: Seizures2414(58%)10(42%)0.414 Microcephaly2215(68%)7(32%)0.088 Jaundice209(45%)11(55%)0.655 Hepatosplenomegaly1510(66%)5(33%)0.197 Calcification22(100%)0(0%)-- Others (e.g. hydrocephaly, anemia, meningitides, fever, loss of hearing)1710(59%)7(41%)0.467

Urine and serum samples were collected from recruited neonates to look for the virus DNA and specific IgG and IgM against cytomegalovirus, respectively. Fluorescent End Point (FEP) PCR showed excretion of CMV-DNA in urine of 58 newborns, yielding a prevalence rate of CMV congenital infection of 58% among symptomatic congenital infants in Tehran. In the total population studied, the CMV-IgG antibody was found in 59 of 100, of which only 40 (68%) were positive for CMV DNA in their urine samples. Twenty cases (34%) had CMV-IgM high titers and CMV DNA was detected in the urine of all these patients. CMV DNA was not detected in the urine of 19 (32%) IgG- positive patients. Of the 41 CMV IgG negative patients, 18 cases (44%) were found to be positive for urine CMV-DNA by PCR (Table [3](#Tab3){ref-type="table"}).Table 3Results of IgG, IgM ELISA and PCR for detecting congenital CMV in symptomatic infantsNo of infantsIgGIgMPosNegPosNegPCR positive5840182038PCR negative421923042Total10059412080

Our statistical analysis showed that there was a significant difference between the results of PCR and IgM measurement used for CMV infection diagnosis in symptomatic neonates (*p* \< 0.001). The difference between the results of PCR and IgG serologic test in the same patients was also significant (*p* = 0.017).

The sensitivity and specificity of IgG measurement compared with PCR technique were 69% (CI; 95% (55.5--80.5%) and 54.8% (CI: 95% (38.7% -70.2%)), respectively. Whereas these values for IgM serologic test compared to PCR were 34.5% (CI: 95% (22.5% - 48.1%) and 100% (CI: 95% (91.6%--100%), respectively.

Compared to PCR the PPV for IgG and IgM were 67.8% and 100%, respectively and the NPV values for the same tests were 56.1% and 52.5%, respectively.

Discussion {#Sec8}
==========

The main goal of this study was to assess the prevalence of congenital CMV in symptomatic infants less than 3 weeks old and compare DNA-PCR method with serologic assays for diagnosis of CMV infection. However, since there is a possibility of postnatal acquisition of virus, accurate diagnosis can not be made if testing is performed after 3 weeks of birth.

The prevalence of cCMV infection in symptomatic infants in Iran has not been determined and the few available reports deal mainly with the infection in pregnant women \[[@CR19]--[@CR22]\]**.**Javid et al. (2016) in a screening study, tested 2000 urine samples of newborns, under 3 weeks of birth to diagnose the congenital CMV infections in Gorgan, in the north of Iran, south east of Caspian sea. In which, 13 out of 2000 urine samples were reported to be positive for CMV, by using DNA amplification technique. The prevalence of CMV in their study was 0.65% in all symptomatic and asymptomatic infants \[[@CR23]\].

In developed countries, the prevalence of prenatal CMV infection of infants varies from 0.3% to 2.3% \[[@CR24]\]. This value in developing countries is more variable both within and between countries, with some reported prevalences as high as 6--14% \[[@CR4], [@CR5]\]. According to the available data, more than 40,000 infants are born with congenital CMV infection in USA annually, 100 times more than those with toxoplasmosis \[[@CR25]\]. The population of our study consisted of 100 infants who were characterized by the symptoms listed in Table [2](#Tab2){ref-type="table"} and were considered as suspected of symptomatic infections. The most common symptoms were related to respiratory problems, seizures and microcephaly, 31%, 24%, and 22%, respectively.

In the current study most of the infants had more than one clinical symptom. In a systematic literature review on 11 studies from developing countries from Africa, Asia, and Latin America, the CMV birth rates ranged from 0.6% to 6.1% \[[@CR26]\]. Of the studies they reviewed, the proportion classified as symptomatic was 0--29%, which is similar to estimates of 5--20% from studies in developed countries \[[@CR27]\].

According to the data from developed countries, an estimated 40--58% of newborns with symptomatic cCMV infection at birth are expected to have permanent neurodevelopmental disabilities. In developing countries, additional stresses on infants health, along with higher birth prevalence could augment disability due to cCMV infection.

Use of appropriate tests for diagnosis of cCMV infection at birth is essential and different techniques are now available for CMV screening including PCR based methods \[[@CR16], [@CR28]--[@CR31]\]. Many studies have shown that the sensitivity and specificity of PCR is 97--100%, when measured against CMV culture. The high sensitivity of PCR makes the detection of even very low amounts of viral particles in the specimens possible \[[@CR17], [@CR28], [@CR32], [@CR33]\]. Several studies have used urine samples as the specimen of choice for looking for CMV-DNA in neonates, which unlike blood can be collected in a non-invasive method, giving a positive result even when the virus is inactive \[[@CR34], [@CR35]\]. The traditional culture-based CMV viral isolation from urine or saliva within the first 3 weeks of life is the gold standard for diagnosis of cCMV infection in newborns \[[@CR12], [@CR36], [@CR37]\], but the method is labor- and resource-intensive. CMV-DNA detection in urine by PCR is a sensitive, reliable, rapid, cost effective and convenient method to diagnose cCMV infection \[[@CR38]\]. In PCR based detection of CMV, there is no need for live virus for detection of the infection, so, the test would not be affected by different conditions of storage and transport. All of these characteristics has made the results of PCR comparable with those from tissue culture, the gold standard diagnostic technique for CMV \[[@CR39], [@CR40]\].

In our study, viral DNA was detected in the urine of 58 out of 100 symptomatic infants, yielding a prevalence rate of cCMV infection of 58% in symptomatic neonates in Tehran. Positive controls were also used to avoid false negatives. Among CMV infected infants IgM antibody was detected in only 34% (20/58).

Although, the primary infection is characterized by CMV IgM antibodies, our results have showed low sensitivity of CMV IgM antibodies (34.5%) in diagnosing congenital infection which is consistent with those reported by the other studies(20--70%) \[[@CR41]\]. It should be considered that IgM-CMV elevated titers might be due to the responses against other viral infections such as Epstein -Barr, with some cross reactivity with CMV antigens. Furthermore, IgM might persist for a long time following primary infection. Therefore, IgM alone could not be the test of choice for CMV diagnosis.Norbakhsh et al., in a case and control study with matching age in Iran, found that the CMV antibodies (IgM, IgG) were positive in 41.9% (31/74) and 74% (54/74) of cases, respectively \[[@CR42]\].

Moreover, some assays in adults and infants older than 3 weeks have shown that IgM antibody lack sufficient specificity for detection of primary infection due to false-positive results, since IgM can persist for months after primary infection, as well as beingpositive in reactivated CMV infections \[[@CR43]--[@CR45]\]. In addition IgM might be falsely negative in more than 50% of infected newborns, as seen in our study. In our study, of the 59 IgG positive infants only 40 (67.79%) had secreted CMV-DNA in their urine and the remaining 19 IgG positive infants did not excrete CMV-DNA in the their urine. These results highlight the poor association of IgG antibody titer and active CMV infection showing that serologic diagnostic results have limited validation for CMV diagnosis. Positive serologic test for CMV IgG antibody in the newborns, may be an indication of passive transfer of maternal antibody, although a negative test makes cCMV infection in infants unlikely. To our knowledge this is the first report outlining the molecular detection of cCMV in the urine of symptomatic congenital infections in Iranian newborns. The data presented in this study are consistent with the world average of cCMV prevalence (40--58%) in symptomatic infants reported by other studies \[[@CR27], [@CR46], [@CR47]\].

Conclusions {#Sec13}
===========

Our findings showed the high prevalence of CMV infection in symptomatic newborns in Tehran. Therefore, PCR assay for detection of CMV-DNA in neonates immediately after delivery is recommended for early treatment and prevention of post infection problems. In addition, our study showed that serologic markers (IgM and IgG titers) are not reliable for diagnosis of congenital infection.
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